Insulet Gains 77.2% in a Year: What's Driving the Rally?

Key Takeaways Insulet shares jumped 77.2% in a year, far outpacing its industry and the S&P 500 Composite.PODD's Omnipod 5 gained FDA clearance for type 2, expanding access to over 5.5 million U.S. patients.PODD's Q2 2025 operating profit jumped 122.2% with margin gains, driven by strong revenues across segments.Insulet Corporation (PODD) has witnessed strong momentum in the past year. Shares of the company have risen 77.2%, outperforming 4.6% growth of the industry during the same time frame. The S&P 500 C ...